Novartis' (NVS) LCZ696 drug for patients with ejection fraction heart failure, in which the...
Sunday, August 26, 2012, 4:51 AM ETNovartis' (NVS) LCZ696 drug for patients with ejection fraction heart failure, in which the organ's chambers are stiff but can still pump a reasonable amount of blood, performed well in a mid-stage trial. LCZ696 reduced levels of NT-proBNP, a protein that's linked to the condition. Larger studies are now needed to see whether this "biomarker" can lead to improved results in clinical practice.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles